It seems pretty logical…

You want to own the company that’ll manufacture and supply the United States (and perhaps even the world) with the COVID-19 vaccines, right?

The gains could be enormous – especially on the day that this world-changing news gets announced.

But the problem is…

How do you identify and invest in the one company that’ll emerge as the winner?

A simple Google search shows that 23 of the world’s largest biotech and pharma companies are actively working on coronavirus treatments or vaccines.

You already know that this group includes Pfizer, Gilead Sciences, Regeneron and Moderna.

Break this down even more and you’ll find a collection of companies making vaccines, treatments and testing kits.

And many of them are smaller biotech companies that you’ve never even heard of.

So again, aside from throwing a dart and hoping that it lands in the bull’s-eye…

How on Earth do you pick a winner?

Today, I have that answer for you…

And it comes in the form of the SPDR S&P Biotech ETF (NYSE: XBI).

Unlike with other biotech exchange-traded funds (ETFs), I like the SPDR S&P Biotech ETF because it emphasizes small cap growth.

Its top 10 holdings all represent potential diamonds in the rough that could easily emerge as top COVID-19 candidates in no time.

This list includes:

• Inovio Pharmaceuticals
• Invitae
• Novavax
• Amicus Therapeutics
• Opko Health
• Arrowhead Pharmaceuticals
• Natera
• Alkermes
• Alnylam Pharmaceuticals
• Esperion Therapeutics.

Not familiar with most of these?

You’re not alone. And that’s why I think the SPDR S&P Biotech ETF is such a winner.

Action Plan: I like the idea of having cheap upside exposure to the biotech sector – especially the smaller, more exciting names in the group. In my view, the very best way to own an entire basket of the most promising biotech stocks on the market today is by owning the SPDR S&P Biotech ETF. Consider adding it to your ledger now!

P.S. Yesterday, War Room members took a one-day winner trading the SPDR S&P Biotech ETF. Do you want to hit these winners in real time? Then you’re invited to join me in The War Room today!

Take a look at what some members had to say about the SPDR S&P Biotech ETF yesterday…

“In at $2.20 out at $2.95. Very nice trade this AM. Nice way to start the first day back from the 4th. Up $75.00 per contract. A very nice 35% gain. Thanks Bryan.” – Rick R.

“In at $2.32, out at $3.04, 31% gain on 2 contracts.” – Charles S.

“In at $2.27 out at $3.11 A whopping 37% in an hour. Awesome! Thanks BB!” – Anam M.

“Got in at $2.30 out at $3.15 for a cool 37%. Thank you.” – Dave H.